A new theranostic contact lens has been developed that monitors intraocular pressure (IOP) and administers glaucoma medications. Preliminary studies in rabbits show reliable performance in both monitoring and drug delivery, addressing adherence issues in glaucoma treatment.
Background
Glaucoma is a leading cause of irreversible blindness, often undetected until significant vision loss occurs. Current treatment methods rely on periodic IOP measurements and daily medication, which can lead to poor adherence. The development of a contact lens that combines real-time monitoring and drug delivery could significantly improve patient outcomes.
Data Highlights
Preliminary studies demonstrated the lens's ability to monitor IOP and release medication effectively in both live rabbit eyes and ex vivo cow eyes.
Key Findings
The smart contact lens monitors ocular pressure without electronics or batteries.
It releases medication in response to changes in corneal shape due to IOP fluctuations.
Initial tests showed reliable performance in both ocular hypertensive and control groups.
The lens is designed for comfort and tailored to individual vision needs.
Potential for broader applications in other conditions due to its drug-release mechanism.
Clinical Implications
This innovative contact lens could enhance patient adherence to glaucoma treatment by providing real-time monitoring and automated medication delivery. Its design may also reduce discomfort associated with existing monitoring devices.
Conclusion
The development of this theranostic contact lens represents a promising advancement in glaucoma management, with the potential to improve patient outcomes through enhanced monitoring and adherence.
